25.48% to Target, Deutsche Bank Reconfirms Buy Rating for Voya Financial (VOYA) Stock; Akebia Therapeutics (AKBA) Sentiment Is 1.63

April 17, 2018 - By Martha Paddon

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Logo

Akebia Therapeutics (AKBA) investors sentiment decreased to 1.63 in 2017 Q4. It’s down -0.60, from 2.23 in 2017Q3. The ratio has worsened, as 70 hedge funds increased and opened new holdings, while 43 sold and trimmed holdings in Akebia Therapeutics. The hedge funds in our database reported: 30.27 million shares, up from 28.78 million shares in 2017Q3. Also, the number of hedge funds holding Akebia Therapeutics in top ten holdings was flat from 0 to 0 for the same number . Sold All: 15 Reduced: 28 Increased: 44 New Position: 26.

New York: In a note made public on Tuesday morning, Deutsche Bank reconfirmed their Buy rating on shares of Voya Financial (NYSE:VOYA). They currently have a $66 TP on the company. Deutsche Bank’s target gives a potential upside of 25.48% from the company’s last price.

Voya Financial, Inc. operates as a retirement, investment, and insurance firm in the United States. The company has market cap of $9.02 billion. It operates through five divisions: Retirement, Investment Management, Annuities, Individual Life, and Employee Benefits. It currently has negative earnings. The Retirement segment offers tax-deferred employer-sponsored retirement savings plans and administrative services in corporate, education, healthcare, and other non-profit and government entities; and rollover individual retirement accounts and other retail financial products, as well as financial planning and advisory services.

Investors sentiment increased to 0.98 in 2017 Q4. Its up 0.24, from 0.74 in 2017Q3. It improved, as 24 investors sold Voya Financial, Inc. shares while 124 reduced holdings. 58 funds opened positions while 87 raised stakes. 179.07 million shares or 6.24% more from 168.54 million shares in 2017Q3 were reported. 124,296 were reported by Great West Life Assurance Company Can. Pictet Asset Mgmt Ltd invested in 72,753 shares. Toth Financial Advisory invested 0.25% in Voya Financial, Inc. (NYSE:VOYA). Putnam Invests Ltd Limited Liability Company owns 87,339 shares. Stratos Wealth Ptnrs accumulated 644 shares. 203,886 are held by Highbridge Cap Management Limited Liability Co. Vanguard Gp Incorporated Inc stated it has 15.03M shares. Goldman Sachs Gru Inc reported 0.01% in Voya Financial, Inc. (NYSE:VOYA). State Of Wisconsin Investment Board invested 0.02% of its portfolio in Voya Financial, Inc. (NYSE:VOYA). Clear Harbor Asset Management Ltd Liability holds 1.1% of its portfolio in Voya Financial, Inc. (NYSE:VOYA) for 117,780 shares. Lsv Asset Mgmt owns 2.66M shares. Dimensional Fund Advsr Ltd Partnership reported 0.02% of its portfolio in Voya Financial, Inc. (NYSE:VOYA). Pekin Singer Strauss Asset Management Il invested in 108,976 shares or 0.99% of the stock. Portolan Cap Mngmt Lc holds 0.84% or 155,016 shares in its portfolio. Tudor Invest Et Al stated it has 14,637 shares.

Analysts await Voya Financial, Inc. (NYSE:VOYA) to report earnings on May, 1 after the close. They expect $0.86 EPS, up 6.17% or $0.05 from last year’s $0.81 per share. VOYA’s profit will be $147.51 million for 15.29 P/E if the $0.86 EPS becomes a reality. After $0.87 actual EPS reported by Voya Financial, Inc. for the previous quarter, Wall Street now forecasts -1.15% negative EPS growth.

The stock increased 1.15% or $0.6 during the last trading session, reaching $52.6. About 600,621 shares traded. Voya Financial, Inc. (NYSE:VOYA) has risen 34.91% since April 17, 2017 and is uptrending. It has outperformed by 23.36% the S&P500.

Since February 21, 2018, it had 0 insider purchases, and 2 selling transactions for $328,755 activity. SILVA KEVIN D sold $283,316 worth of Voya Financial, Inc. (NYSE:VOYA) on Tuesday, March 6.

Among 18 analysts covering Voya Financial (NYSE:VOYA), 14 have Buy rating, 1 Sell and 3 Hold. Therefore 78% are positive. Voya Financial has $66 highest and $29 lowest target. $55.29’s average target is 5.11% above currents $52.6 stock price. Voya Financial had 46 analyst reports since August 26, 2015 according to SRatingsIntel. The company was maintained on Thursday, December 21 by RBC Capital Markets. On Monday, July 10 the stock rating was maintained by RBC Capital Markets with “Buy”. The company was maintained on Thursday, July 14 by Deutsche Bank. The firm earned “Buy” rating on Wednesday, November 1 by RBC Capital Markets. Wells Fargo maintained the stock with “Buy” rating in Thursday, March 1 report. The rating was maintained by Keefe Bruyette & Woods with “Buy” on Tuesday, July 25. JP Morgan downgraded the stock to “Underweight” rating in Tuesday, January 3 report. The firm earned “Buy” rating on Wednesday, January 10 by Sandler O’Neill. On Monday, November 13 the stock rating was upgraded by Sandler O’Neill to “Buy”. The rating was initiated by Wells Fargo with “Market Perform” on Friday, September 23.

The stock decreased 0.60% or $0.06 during the last trading session, reaching $9.89. About 95,947 shares traded. Akebia Therapeutics, Inc. (AKBA) has risen 5.85% since April 17, 2017 and is uptrending. It has underperformed by 5.70% the S&P500.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology. The company has market cap of $554.95 million. The Company’s lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. It currently has negative earnings. The firm is also developing a HIF portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease.

Nantahala Capital Management Llc holds 1.28% of its portfolio in Akebia Therapeutics, Inc. for 1.93 million shares. Dafna Capital Management Llc owns 135,738 shares or 1.09% of their US portfolio. Moreover, Perceptive Advisors Llc has 0.98% invested in the company for 1.99 million shares. The California-based Eam Investors Llc has invested 0.46% in the stock. Opus Point Partners Management Llc, a New York-based fund reported 21,009 shares.

Analysts await Akebia Therapeutics, Inc. (NASDAQ:AKBA) to report earnings on May, 8. They expect $-0.68 earnings per share, up 40.87% or $0.47 from last year’s $-1.15 per share. After $0.25 actual earnings per share reported by Akebia Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -372.00% negative EPS growth.

Ratings analysis reveals 100% of Akebia Therapeutics’s analysts are positive. Out of 3 Wall Street analysts rating Akebia Therapeutics, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. AKBA was included in 3 notes of analysts from September 29, 2016. The rating was initiated by Brean Capital on Thursday, September 29 with “Buy”. Aegis Capital initiated the stock with “Buy” rating in Tuesday, November 15 report. H.C. Wainwright maintained the stock with “Buy” rating in Tuesday, December 27 report.

Voya Financial, Inc. (NYSE:VOYA) Institutional Positions Chart